{"id":"W3191692701","doi":"10.1038/s41591-021-01455-x","title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Agence Nationale de la Recherche","keywords":"Progressive supranuclear palsy; Placebo; Discontinuation; Clinical endpoint; Medicine; Internal medicine; Surrogate endpoint; Randomized controlled trial; Adverse effect; Clinical trial; Gastroenterology; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001720458,0.002585221,0.004131309,0.0005455436,0.0005327706,0.001167379,0.001143831,0.00267058,0.005167628],"category_scores_gemma":[0.001695807,0.0008604082,0.002259638,0.0004627333,0.001680156,0.001563354,0.0003896674,0.003383845,0.0009847169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008453517,"about_ca_system_score_gemma":0.001034377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008240372,"about_ca_topic_score_gemma":0.001713741,"domain_scores_codex":[0.9993437,0.0002752555,0.00004407921,0.0001555053,0.0000664818,0.0001149283],"domain_scores_gemma":[0.9992515,0.0002278563,0.0001941579,0.00006119519,0.00006291576,0.0002023767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9776233,0.00432669,0.0004476598,0.0008242444,0.001272156,0.00005973879,0.00004394716,0.0002366747,0.002776863,0.00008053296,0.0005299468,0.01177822],"study_design_scores_gemma":[0.9432861,0.05380125,0.001152992,0.00004395657,0.0006500679,0.00003365061,0.00002037899,0.0001919387,0.0003160662,0.0001188086,0.0003695929,0.00001514261],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784443,0.01364235,0.0007161482,0.0006981121,0.0007062334,0.002805262,0.0008520324,0.0001287856,0.002006785],"genre_scores_gemma":[0.983967,0.006547801,0.001088602,0.001135014,0.0006327207,0.002895592,0.0009560866,0.0000300147,0.002747065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005167628,"threshold_uncertainty_score":0.01728743,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008747660753057256,"score_gpt":0.3242055735514162,"score_spread":0.3154579127983589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}